Related Experiment Video
Updated: Aug 24, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors
Tae-Sook Jeong1, Kyung Soon Kim, Sojin An
1National Research Laboratory of Lipid Metabolism and Atherosclerosis, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, South Korea.
Abstract:
A series of pyrazoline derivatives were prepared for evaluating their acyl-CoA:cholesterol acyltransferase activities. 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)-5-(multi-substituted 4-hydroxyphenyl)-2-pyrazolines 4a-i were shown in vitro inhibitory activity on hACAT-1 and -2.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Oral Hypoglycemic Agents: Biguanides and Glitazones
